3d Printed Drugs Market

According to Stratistics MRC, the Global 3D Printed Drugs Market is accounted for $99.09 million in 2023 and is expected to reach $302.79 million by 2030 growing at a CAGR of 17.3% during the forecast period. The market for 3D-printed drugs consists of pharmaceuticals that are made specifically for each patient in a safer and more efficient manner using 3D printing technology. These medications do not have to be ingested completely because of their unitary porous architecture, which easily disperses in the mouth. Therefore, patients who frequently have swallowing issues, children, the elderly, and those suffering from the effects of stroke, Alzheimer's disease, head and neck cancers, and other neurological problems can all benefit from this type of drug.

According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018.



Market Dynamics:

Driver:

Rapid production and prototyping and complex medication delivery techniques

A rapid and affordable alternative for producing prototypes and developing pharmaceuticals is 3D printing. It reduces the need for time- and money-consuming traditional manufacturing procedures like injection molding and tablet compression. Additionally, with precise control over medication release features, complex drug delivery systems can be made through 3D printing. By targeting particular regions of the body and improving drug delivery, this technique can increase the efficacy and safety of medications.

Restraint:

Complex manufacturing processes and regulatory hurdles

Obtaining regulatory approval for these products is difficult, as the regulatory environment for 3D-printed drugs is still developing. A strong regulatory framework and set of criteria must be established in order to guarantee the safety, quality, and effectiveness of 3D-printed drugs. However, specialized tools and knowledge are needed to implement 3D printing technology in the pharmaceutical production industry. The infrastructure for 3D printing can be expensive to set up and maintain, necessitating substantial investments.

Opportunity:

Rising disease prevalence

For instance, pneumonia kills more children than any other infectious disease and causes about 2,000 deaths each day. Newborns make up more than 200,000 of them. Therefore, due to 3D-printed medications, taking medication could become a lot simpler for kids who are averse to doing so. The possibility of customizing the tablet's taste, color, and style is the first advantage of these tablets. The rising adoption of these medications is being influenced by the rising incidence of pediatric disorders, which is expected to fuel the market for 3D-printed drugs globally over the next few years.

Threat:

The cost of 3D printing technology is high

Small and medium-sized pharmaceutical enterprises might find it challenging to embrace 3D printing technology due to the high initial cost of the necessary hardware, software, and materials. However, due to the high cost of materials and the period of time needed for production, 3D-printed pharmaceuticals may have higher prices per unit than conventional drugs. This may lower patient access to 3D-printed medications and lower demand for these products.

Covid-19 Impact:

The use of 3D printing has increased as a result of the COVID-19 outbreak. To assist with the creation of medicines and other necessary products, the operational individuals in the advanced manufacturing industry have introduced a number of 3D printers. Additionally, the COVID-19 pandemic's drug shortages have drawn pharmaceutical companies' attention to the idea of using 3D printing technology to supply medications rapidly. The COVID-19 pandemic is projected to have a favorable effect on market expansion. The operation of businesses in the advanced manufacturing sector has introduced a number of printers to aid in boosting the production of medicines and other essential products. Therefore, it is anticipated that the use of these technologies will grow during the COVID-19 pandemic.

The neurology segment is expected to be the largest during the forecast period

Neurology segment commanded the largest share over the projection period, due to the rise in prevalence of certain neurological conditions, such as Parkinson's disease. For instance, The U.S. FDA approved Aprecia Pharmaceutical's SPRITAM (levetiracetam) tablets in August 2015 as the only approved drug on the market for the treatment of people with epilepsy. This approval has attracted pharmaceutical companies' attention to invest in this segment, driving market growth. Additionally, in an article published in April 2022, a group of scientists from Germany and the Netherlands revealed how they created the Mini-Floating Polypill as a Parkinson's disease treatment using 3D printing technology. This study made use of fused deposition modeling (FDM).

The thermal inkjet printing segment is expected to have the highest CAGR during the forecast period

Thermal Inkjet Printing segment is estimated to witness the highest CAGR over the extrapolated period. Thermal Inkjet Printing is a non-contact printing technology that utilizes heat to drive microscopic droplets of ink onto a substrate, creating high-resolution pictures or patterns. In the context of 3D printed therapeutics, thermal inkjet printing technology allows for the accurate deposition of pharmaceutical ingredients, enabling the fabrication of tailored medications with specified dosages and compositions. Moreover, the technology is reasonably economical compared to other 3D printing processes, making it accessible to pharmaceutical companies of varying sizes.

Region with largest share:

Due to an increased prevalence of chronic diseases, the availability of an outstanding domestic healthcare infrastructure, significant investment in R&D, and the region's expanding utilization of technological advancements, the Asia Pacific region dominated with a majority over the anticipated period. Moreover, the market is expanding due to a number of factors, including the increased need for less expensive medications or tablets and the expanding use of 3D printing in the healthcare industry. Pharmaceuticals produced through 3D printing are gaining popularity as they are simple to consume and almost immediately dissolve.

Region with highest CAGR:

Due to considerable advancements made by China and Japan in the integration of 3D-printed drug techniques into technology, the Asia Pacific is predicted to have the highest rate of development over the projected period. Furthermore, the expansion of clinical development frameworks, R&D, and healthcare infrastructure in developing nations like Australia and India is setting the Asia Pacific market for lucrative growth prospects over the course of the projection period. As a result, rising dysphagia rates and expanding healthcare infrastructure are predicted to drive market expansion.



Key players in the market

Some of the key players in 3D Printed Drugs market include Affinity Therapeutics, Aprecia Pharmaceuticals LLC , Astrazeneca, Bioduro, Cycle Pharmaceuticals, Extend Biosciences, Fabrx Ltd, Glaxosmithkline PLC, Hewlett Packard Caribe and Osmotica Pharmaceuticals.

Key Developments:

In October 2022, Cycle Pharmaceuticals Limited (Cycle) announced the launch of JAVYGTOR (sapropterin dihydrochloride) Tablets for Oral Use and Powder for Oral Solution, as a treatment option for patients with Phenylketonuria (PKU), approved by the US Food and Drug Administration (FDA). The launch of JAVYGTOR continues an established partnership between Cycle and Dr Reddy's Laboratories Ltd, in which the two companies are committed to providing affordable medicines to patients with rare diseases, complemented by the support these patients need.

Dosage Forms Covered:
• Nanoparticles
• Multidrug Implant
• Solutions
• Tablet
• Other Dosage Forms

Technologies Covered:
• Semi Solid Extrusion (SSE)
• Stereolithography (SLA)
• Powder Bed Printing
• Thermal Inkjet Printing
• Zip Dose
• Direct Write
• Fused Deposition Modelling
• Selective Laser Sintering
• Other Technologies

Applications Covered:
• Dental
• Neurology
• Orthopedic
• Children
• Elderly
• Other Applications

End Users Covered:
• Research Laboratories
• Hospitals & Clinics
• Other End Users

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances